Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Rose

Internal Medicine Muscle Shoals, AL Medical Doctor

NPI 1215921978 CMS profile 9219

2410 Avalon Ave, Muscle Shoals, AL 35661

Open in the dashboard

General payments

$9,864

663 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Rose of Muscle Shoals, AL is reported in the CMS Open Payments database as having received $9,864 across 663 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $527 26
2024 General $889 61
2023 General $1,139 100
2022 General $1,347 110
2021 General $1,858 150
2020 General $1,846 108
2019 General $2,258 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Rose
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kenneth Rose were reported at $527. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kenneth Rose Internal Medicine median Middle half National median
2019 $2,258 $159 $48–$570 $163
2020 $1,846 $119 $33–$402 $114
2021 $1,858 $135 $37–$521 $132
2022 $1,347 $141 $42–$496 $149
2023 $1,139 $149 $45–$519 $160
2024 $889 $154 $47–$537 $164
2025 $527 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,198 150 payments
  2. Lilly USA, LLC $1,211 97 payments
  3. AstraZeneca Pharmaceuticals LP $784 22 payments
  4. AbbVie, Inc. $760 81 payments
  5. Janssen Pharmaceuticals, Inc $593 37 payments
  6. GlaxoSmithKline, LLC. $526 34 payments
  7. Pfizer Inc. $434 34 payments
  8. Amgen Inc. $354 13 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $335 27 payments
  10. Novartis Pharmaceuticals Corporation $326 19 payments
  11. Other $2,343 149 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,820 658 payments
  2. Education $44 5 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,719 118 payments
  2. RYBELSUS $918 77 payments
  3. FARXIGA $714 17 payments
  4. TRELEGY ELLIPTA $502 32 payments
  5. XARELTO $493 36 payments
  6. INVOKANA $353 25 payments
  7. MOUNJARO $317 22 payments
  8. EMGALITY $306 23 payments
  9. TRULICITY $303 21 payments
  10. UBRELVY $298 41 payments
  11. Other $6,583 462 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 252 drugs

Part D claims

36,308

Median for Internal Medicine: 777

Drug cost

$1,997,109

Median for Internal Medicine: $73,373

Branded share of claims

19.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 202 $240,335
Eliquis Apixaban Brand 687 $240,042
Jardiance Empagliflozin Brand 202 $190,119
Mounjaro Tirzepatide Brand 109 $122,254
Farxiga Dapagliflozin Propanediol Brand 253 $106,590
Xarelto Rivaroxaban Brand 214 $79,129
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 93 $70,205
Januvia Sitagliptin Phosphate Brand 122 $61,964
Otezla Apremilast Brand 11 $53,280
Trulicity Dulaglutide Brand 30 $49,136

The 10 drugs with the highest cost, of 252 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 143 billing codes

Paid by Medicare

$261,481

Of which drugs: $28,337

Medicare patients

1,032

Average age 76

Services billed

9,875

538 women, 494 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 35%
Ischemic heart disease 28%
Chronic kidney disease 25%
Atrial fibrillation 22%
Depression 20%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 38 38 $10,787
Vaccine for influenza for injection into muscle 90662 Office 113 113 $6,977
Sarscv2 vac 30mcg trs-suc im 91320 Office 40 40 $6,111
Injection, ceftriaxone sodium, per 250 mg J0696 Office 42 185 $59
Injection, methylprednisolone acetate, 1 mg J1010 Office 29 540 $53
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 19 53 $51
Injection, methylprednisolone acetate, 40 mg J1030 Office 14 17 $50
Injection, ketorolac tromethamine, per 15 mg J1885 Office 15 66 $28
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 43 68 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$135 — —
Ozempic
$126 202 —
MOUNJARO
$69 109 —
ZEPBOUND
$62 — —
VOQUEZNA
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

663 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record